(Q46874421)

English

Impact of total PSA, PSA doubling time and PSA velocity on detection rates of 11C-Choline positron emission tomography in recurrent prostate cancer

scientific article published on 20 July 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/22814886

Impact of total PSA, PSA doubling time and PSA velocity on detection rates of 11C-Choline positron emission tomography in recurrent prostate cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/22814886

positron emission tomography

1 reference

based on heuristic

inferred from title

author name string

Maxim Rybalov

1

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/22814886

Anthonius J Breeuwsma

2

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/22814886

Anna M Leliveld

3

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/22814886

Jan Pruim

4

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/22814886

Rudi A Dierckx

5

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/22814886

Igle J de Jong

6

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/22814886

publication date

20 July 2012

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/22814886

World Journal of Urology

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/22814886

31

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/22814886

2

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/22814886

319-323

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/22814886

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0908-Z

21 January 2018

Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0908-Z

21 January 2018

Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes.

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0908-Z

21 January 2018

Detection of local, regional, and distant recurrence in patients with psa relapse after external-beam radiotherapy using (11)C-choline positron emission tomography

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0908-Z

21 January 2018

Implications of prostate-specific antigen doubling time as indicator of failure after surgery or radiation therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0908-Z

21 January 2018

Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0908-Z

21 January 2018

PSA doubling time for prediction of [(11)C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0908-Z

21 January 2018

Prostate-specific antigen kinetics in localized and advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0908-Z

21 January 2018

Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography.

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0908-Z

21 January 2018

11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0908-Z

21 January 2018

The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0908-Z

21 January 2018

11C-choline and 2-deoxy-2-[18F]fluoro-D-glucose in tumor imaging with positron emission tomography

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0908-Z

21 January 2018

FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0.

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0908-Z

21 January 2018

Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0908-Z

21 January 2018

Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0908-Z

21 January 2018

Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22814886

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22814886

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel

1 reference

https://pubmed.ncbi.nlm.nih.gov/22814886

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22814886

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prostate-specific antigen recurrence and mortality after conventional dose radiation therapy in select men with low-risk prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22814886

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml

1 reference

https://pubmed.ncbi.nlm.nih.gov/22814886

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/22814886

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Methods of calculating prostate-specific antigen velocity

1 reference

https://pubmed.ncbi.nlm.nih.gov/22814886

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00345-012-0908-Z

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/22814886

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/22814886

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46874421&oldid=2208199523"